Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Immunotoxin toxin

WHO (2004) concluded that The mono- and disubstituted compounds that may leach from PVC water pipes for a short time after installation are primarily immunotoxins although they appear to be of low general toxicity, some are developmental toxins in rodents. The data available are insufficient to permit the proposal of guideline values for individual dialkyltins or the mono derivatives, although the concentrations observed in drinking-water are several orders of magnitude lower than the doses reported to cause developmental effects in rats and mice. ... [Pg.43]

Figure 21.1 The basic design of an immunotoxin conjugate consists of an antibody-targeting component crosslinked to a toxin molecule. The complexation typically includes a disulfide bond between the antibody portion and the cytotoxic component of the conjugate to allow release of the toxin intracellularly. In this illustration, an intact A-B toxin protein provides the requisite disulfide, but the linkage also may be designed into the crosslinker itself. Figure 21.1 The basic design of an immunotoxin conjugate consists of an antibody-targeting component crosslinked to a toxin molecule. The complexation typically includes a disulfide bond between the antibody portion and the cytotoxic component of the conjugate to allow release of the toxin intracellularly. In this illustration, an intact A-B toxin protein provides the requisite disulfide, but the linkage also may be designed into the crosslinker itself.
Since immunotoxin conjugates are destined to be used in vivo, their preparation involves more critical consideration of crosslinking methods than most of the other conjugation protocols described in this book. The following sections discuss the problems associated with toxin conjugates and the main crosslinking methods for preparing them. [Pg.829]

A-chain immunotoxins, however, may not be quite as cytotoxic as conjugates formed from intact toxin molecules (Manske et al., 1989). In an alternative approach to A chain use, the intact toxin of two-subunit proteins is directly conjugated to a monoclonal without isolation of the A chain. Conjugation of an antibody with intact A-B chain toxins can be done without a cleavable linker, as long as the A chain can still separate from the B chain once it is internalized. Therefore, it is important to avoid intramolecular crosslinking during the conjugation process which can prevent release of the A-B complex. In addition, since the B chain... [Pg.830]

Figure 21.7 An intact A-B subunit toxin molecule may be activated with 2-iminothiolane with good retention of cytotoxic activity. The thiolated toxin then may be conjugated with SPDP-activated antibody to generate the immunotoxin conjugate through a disulfide bond. Figure 21.7 An intact A-B subunit toxin molecule may be activated with 2-iminothiolane with good retention of cytotoxic activity. The thiolated toxin then may be conjugated with SPDP-activated antibody to generate the immunotoxin conjugate through a disulfide bond.
SMPT often is used in place of SPDP for the preparation of immunotoxin conjugates. The hindered disulfide of SMPT has distinct advantages in this regard. Thorpe et al. (1987) showed that SMPT conjugates had approximately twice the half-life in vivo as SPDP conjugates. Antibody-toxin conjugates prepared with SMPT possess a half-life in vivo of up to 22 hours, presumably due to the decreased susceptibility of the hindered disulfide toward reductive cleavage. [Pg.841]

Figure 21.8 SMPT may be used to form immunotoxin conjugates by activation of the antibody component to form a thiol-reactive derivative. Reduction of an A-B toxin molecule with DTT can facilitate subsequent isolation of the A chain containing a free thiol. Mixing the A-chain containing a sulfhydryl group with the SMPT-activated antibody causes immunotoxin formation through disulfide bond linkage. The hindered disulfide of an SMPT crosslink has been found to survive in vivo for longer periods than conjugates formed with SPDP. Figure 21.8 SMPT may be used to form immunotoxin conjugates by activation of the antibody component to form a thiol-reactive derivative. Reduction of an A-B toxin molecule with DTT can facilitate subsequent isolation of the A chain containing a free thiol. Mixing the A-chain containing a sulfhydryl group with the SMPT-activated antibody causes immunotoxin formation through disulfide bond linkage. The hindered disulfide of an SMPT crosslink has been found to survive in vivo for longer periods than conjugates formed with SPDP.
Figure 21.10 Cystamine may be used to make immunotoxin conjugates by a disulfide interchange reaction. Modification of antibody molecules using an EDC-mediated reaction creates a sulfhydryl-reactive derivative. A-chain toxin subunits containing a free thiol can be coupled to the cystamine-modified antibody to form disulfide crosslinks. Figure 21.10 Cystamine may be used to make immunotoxin conjugates by a disulfide interchange reaction. Modification of antibody molecules using an EDC-mediated reaction creates a sulfhydryl-reactive derivative. A-chain toxin subunits containing a free thiol can be coupled to the cystamine-modified antibody to form disulfide crosslinks.
However, since SMCC forms nonreversible thioether linkages with sulfhydryl groups, it only can be used in the preparation of immunotoxins if intact A-B toxins are employed in the conjugate. In such conjugates, the A chain still have the potential for reductive release from the B-chain subunit after cellular docking and internalization. Immunotoxins prepared with A-chain or single-subunit toxins will not display cytotoxicity if crosslinked with SMCC, since the crosslinker does not create cleavable disulfide bonds upon conjugation. [Pg.850]

Figure 21.13 Sulfo-SMCC may be used to activate antibody molecules for coupling to thiolated toxin components. An intact A-B toxin molecule can be modified to contain sulfhydryls by treatment with 2-iminothiolane. Thiolation with this reagent retains the cytotoxic properties of the toxin while generating a sulfhydryl for conjugation. Reaction of the thiolated toxin with the maleimide-activated antibody creates the immunotoxin through thioether bond formation. Figure 21.13 Sulfo-SMCC may be used to activate antibody molecules for coupling to thiolated toxin components. An intact A-B toxin molecule can be modified to contain sulfhydryls by treatment with 2-iminothiolane. Thiolation with this reagent retains the cytotoxic properties of the toxin while generating a sulfhydryl for conjugation. Reaction of the thiolated toxin with the maleimide-activated antibody creates the immunotoxin through thioether bond formation.
Figure 21.14 Activation of an intact A-B toxin molecule with MBS with subsequent conjugation with a reduced antibody fragment to produce an immunotoxin. Figure 21.14 Activation of an intact A-B toxin molecule with MBS with subsequent conjugation with a reduced antibody fragment to produce an immunotoxin.
The method for the preparation of immunotoxins with SMPB is identical to that used for MBS (above). Since the thioether bonds formed with sulfhydryl-containing molecules are non-cleavable, A-chain isolates or single-chain toxin molecules can not be conjugated with antibodies with retention of cytotoxicity. Only intact A-B toxin molecules may be used with this crosslinker, since the A chain still is capable of being reductively released from the complex. [Pg.855]

Figure 21.15 A periodate-oxidized dextran polymer may be reacted with both an antibody and an intact toxin component using reductive amination to form a multivalent immunotoxin complex. Figure 21.15 A periodate-oxidized dextran polymer may be reacted with both an antibody and an intact toxin component using reductive amination to form a multivalent immunotoxin complex.
Dell Arciprete, L., Colombatti, M., Rappuoli, R., and Tridente, G. (1988) A C terminus cysteine of diphtheria toxin B chain involved in immunotoxin cell penetration and cytotoxicity./. Immunol. 140, 2466-2471. [Pg.1058]

Jansen, F.L., Blythman, H.E., Carriere, D., Casellas, P., Diaz, J., Gros, P., Hennequin, J.R., Paolucci, F., Pau, B., Poncelet, P., Richer, G., Salhi, S.L., Vidal, H., and Voisin, G.A. (1980) High specific cytotoxicity of antibody-toxin hybrid molecules (immunotoxins) for target cells. Immunol. Lett. 2, 97. [Pg.1078]


See other pages where Immunotoxin toxin is mentioned: [Pg.88]    [Pg.248]    [Pg.186]    [Pg.281]    [Pg.287]    [Pg.827]    [Pg.827]    [Pg.827]    [Pg.829]    [Pg.829]    [Pg.830]    [Pg.830]    [Pg.831]    [Pg.832]    [Pg.833]    [Pg.834]    [Pg.834]    [Pg.839]    [Pg.840]    [Pg.844]    [Pg.846]    [Pg.847]    [Pg.847]    [Pg.848]    [Pg.852]    [Pg.853]    [Pg.855]    [Pg.857]    [Pg.857]    [Pg.452]    [Pg.112]   
See also in sourсe #XX -- [ Pg.854 ]




SEARCH



Immunotoxin

Immunotoxin protein toxins used

Immunotoxins

Immunotoxins toxin properties

Immunotoxins toxins

Immunotoxins toxins

© 2024 chempedia.info